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On April  9,  2014,  Aeras  and  the National  Institute  of Allergy  and  Infectious  Diseases  convened  a  workshop
entitled  “Developing  Aerosol  Vaccines  for Mycobacterium  tuberculosis”  in  Bethesda,  MD.  The  purpose  of
the  meeting  was to explore  the  potential  for developing  aerosol  vaccines  capable  of  preventing  infection
with  M. tuberculosis  (Mtb),  preventing  the  development  of active  tuberculosis  (TB)  among  those  latently
infected  with  Mtb,  or as  immunotherapy  for  persons  with  active  TB.  The  workshop  was  organized  around
four key  questions  relevant  to developing  and  assessing  aerosol  TB  vaccines:  (1)  What  is  the  current
knowledge  about  lung  immune  responses  and  early  pathogenesis  resulting  after  Mtb infection  and  what
are the  implications  for aerosol  TB  vaccine  strategies?  (2)  What  are  the  technical  issues  surrounding
aerosol  vaccine  delivery?  (3)  What  is the  current  experience  in  aerosol  TB  vaccine  development?  and
(4)  What  are  the  regulatory  implications  of  developing  aerosol  vaccines,  including  those  for  TB?  Lessons
learned  from  the  WHO  effort  to develop  an  aerosol  measles  vaccine  served  as  a case  example  for  overall
discussions  at  the meeting.  Workshop  participants  agreed  that aerosol  delivery  represents  a potentially
important  strategy  in  advancing  TB  vaccine  development  efforts.  As no major  regulatory,  manufacturing
or  clinical  impediments  were  identiﬁed,  members  of  the workshop  emphasized  the  need for  greater
support  to further  explore  the  potential  for this  delivery  methodology,  either  alone  or as an  adjunct  to
traditional  parenteral  methods  of  vaccine  administration.ntroduction
Dr. Lewis Schrager, Vice President, Scientiﬁc Affairs, Aeras,
ockville, MD,  USA
Dr. Christine Sizemore, Chief, Tuberculosis, Leprosy
nd other Mycobacterial Diseases Section, DMID/NIAID/NIH
ethesda, MD,  USA
Developing vaccines that can prevent infection and disease
aused by Mycobacterium tuberculosis (Mtb) remains a global health
riority. In his opening remarks, Dr. Lewis Schrager reminded
articipants of the calls for innovative approaches to TB vaccine
Abbreviations: AM,  arabinomannan; BAL, bronchoalveolar lavage; BCG, Bacille
almette-Guérin; CFU, colony-forming units; CBER, center for biologics evaluation
nd  research; CDRH, center for devices and radiological health; CMs, cynomolgus
acaques; DPI, dry powder inhaler; EMA, european medicines association; FDA, U.S.
ood  and drug administration; ID, intradermal; IFN, interferon; IN, intranasal; IRMs,
ndian rhesus macaques; LAM, lipoarabinomannan; MAITs, mucosa-associated
nvariant T-cells; MDR, multidrug-resistant; MMAD, mass median aerodynamic
iameter; Mtb, Mycobacterium tuberculosis; MVA, modiﬁed vaccinia ankara; NAPPA,
ucleic acid programmable protein array; NHP, non-human primate; NIAID, national
nstitute of allergy and infectious diseases; NRA, national regulatory authority;
BMC, peripheral blood mononuclear cells; 18F-PET-CT, (18) ﬂuorodeoxyglucose
adiotracer with positron emission tomography co-registered with computed
omography; PFU, plaque-forming units; pMDI, pressurized metered dose inhaler;
PD, puriﬁed protein derivative; PRNT, plaque reduction neutralization test;
LR,  toll-like receptor; WHO, World Health Organization; XDR, extensively drug
esistant.
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ttp://dx.doi.org/10.1016/j.vaccine.2015.03.060development coming from the Bill and Melinda Gates Founda-
tion and other important supporters of research and development
efforts for TB interventions. He noted that this workshop repre-
sented the ﬁrst meeting to focus speciﬁcally on the potential for
utilizing aerosol delivery as a strategy in TB vaccine development
efforts. While aerosol TB vaccine delivery makes intuitive sense,
given the deep lung site of initial infection following inhalation
and the establishment of granulomas abutting alveolar and deep
bronchial surfaces, the actual potential of this delivery strategy has
only begun to be explored. A number of questions were posed for
workshop participants as they began discussions: (1) for what indi-
cation might an aerosol vaccine strategy be utilized—prevention
of the establishment of Mtb  infection, prevention of the develop-
ment of active disease among persons latently infected with Mtb,
as immunotherapy for those with active TB, or potentially for all
three situations?; (2) what critical scientiﬁc and regulatory bot-
tlenecks exist that might impede the development and testing of
aerosol TB vaccines, and how should these be addressed?; and (3)
is there a consensus as to the potential value of pursuing aerosol
administration when investigating TB vaccine candidates?
Dr. Christine Sizemore stated that NIAID remains committed to
supporting TB biomedical research and translation of fundamental
knowledge about Mtb  and its interaction with its host, into new
drugs, diagnostics and vaccines. As part of this workshop, partici-
pants were urged to think creatively when considering the available
knowledge about TB pathogenesis, local immune responses within
the lung and the potential of aerosolized vaccines to protect against
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nfection or disease progression beyond what may  be achievable
ith vaccines administered by injection. Dr. Sizemore noted that
B causes more than 1.3 million worldwide deaths each year, mak-
ng it the ninth leading cause of global mortality. This, and the
pread of multidrug-resistant (MDR) and extensively drug resis-
ant (XDR) Mtb  strains, lend further urgency to the need for a TB
accine since drug development efforts may  not be able to keep up
ith the spread of drug resistant TB. To increase the potential for
eveloping effective TB vaccines, diverse vaccine candidates and
elivery methods have to be evaluated not only to contribute to
irect product development but also to learn critical information
bout what may  constitute protective immunity against infection
nd disease.
. Session 1: Developing aerosol vaccines for tuberculosis:
eneral considerations
Developing and Testing of Aerosol Measles Vaccines: Lessons
earned. Dr. Ana Maria Henao-Restrepo, Initiative for Vaccine
esearch, Department of Immunization, Vaccines and Biologi-
als, World Health Organization, Geneva, Switzerland
Dr. Ana Maria Henao-Restrepo reviewed some of the important
essons learned from the nine year process of developing an aerosol
easles vaccine through the World Health Organization (WHO)
easles Aerosol Vaccine Project [1–3]. Development of this vaccine
as undertaken as an attempt to facilitate delivery and potentially
xpand measles immunization coverage in developing countries,
articularly in previously overlooked pediatric populations as part
f mass immunization campaigns. Aerosol vaccine delivery could
acilitate mass immunization campaigns due to the relative ease
f this administration strategy as compared to injection given that
rained medical personnel are not required to administer aerosol
accines, because the aerosol vaccine delivery obviates the need
or needle pricks, and because aerosol vaccine administration dra-
atically reduces medical waste, particularly used syringes and
eedles.
An aerosol vaccine combination is being considered for licen-
ure in India. Dr. Henao-Restrepo stressed that development of
erosol vaccine candidates intended for use in the developing world
ecessitated early stage communication with national regulatory
uthorities (NRAs) in the country or countries targeted for vaccine
icensure, as well as stringent regulatory authorities such as the U.S.
ood and Drug Administration (FDA) or the European Medicines
gency (EMA) during vaccine development to ensure that their
arious concerns are addressed in a preemptive manner.
Selecting and characterizing the delivery device for an aerosol
accine is critically important, as the vaccine and device are
icensed as a single combination product (vaccine and delivery
evice) and not as individual, unrelated products. In the aerosol
easles vaccine development effort, the device used in successful
linical studies during the 1990s in Mexico [4] was  used as a refer-
nce device for optimal performance characteristics. Three devices
ere selected from the more than 100 approved aerosolizing
evices that were identiﬁed. Evaluation criteria included particle
ize range and output ﬂows, vaccine potency retention following
erosolization, and practical use in the ﬁeld, including the elimina-
ion of cross-contamination risk, multiple sources for power supply
for example, solar power, batteries, crank system, AC), ease of use,
ncluding size and portability, and ﬁnally, cost.
Dr. Henao-Restrepo concluded her presentation by describing
peciﬁc aspects of aerosol vaccine delivery that required evalua-
ion in preclinical and clinical studies. These included development
f the target product proﬁle, selection of manufacturing processes
hat would result in optimal particle size, selection of the deliv-
ry device, demonstration of vaccine potency retention following33 (2015) 3038–3046 3039
aerosolization, demonstration of immunogenicity, safety and tox-
icity studies in an animal model, evidence of clinical safety and
immunogenicity in immune subjects, immunogenicity in measles-
naïve nine months old infants, and absence of adverse events
potentially associated with aerosol delivery such as exacerbation
of wheezing and central nervous system-associated symptoms.
She noted that the aerosol measles vaccine currently being devel-
oped had completed these steps, including immunogenicity results
obtained from approximately 85 measles-naïve nine month old
infants, determined through a measles plaque reduction neutral-
ization test that was  speciﬁcally established and validated for
use in clinical trials of aerosolized measles vaccines [5]. No seri-
ous adverse events were associated with aerosol vaccine, and the
safety proﬁle was comparable to intramuscular delivery method of
the measles vaccine. When considering the two main options for
aerosol vaccine formulation, a liquid formulation delivered via a
nebulizer and a dry powder formulation delivered via a hand-held
inhaler, the WHO  team preferred the liquid formulation in light
of the long history of immunogenicity and safety of this delivery
strategy in humans, because the formulation already is licensed
for subcutaneous administration and is inexpensive, and in light
of the perceived regulatory familiarity with the nebulized liquid
approach.
Regulatory Considerations in the Development of Aerosol
Vaccines for Tuberculosis. Dr. Roshan Ramanathan, Division
of Vaccines and Related Product Applications, Ofﬁce of Vac-
cine Research and Review, Center for Biologics Evaluation and
Research, FDA, Rockville, MD,  USA. Dr. Deepika Lakhani, Respi-
ratory and Pulmonary Devices Branch, Center for Devices and
Radiological Health, FDA, Silver Spring, MD,  USA
Regulatory issues for aerosol vaccine products were discussed
by FDA reviewers Dr. Roshan Ramanathan (Center for Biologics
Evaluation and Research (CBER)) and Dr. Deepika Lakhani, (Center
for Devices and Radiological Health (CDRH)). Dr. Ramanathan
noted that, from a regulatory standpoint, a product comprised of a
biological product and a device, would be considered a combination
product (http://www.fda.gov/RegulatoryInformation/Guidances/
ucm126050.htm). For most combination products, one Investi-
gational New Drug Application may be submitted for the clinical
investigation of the combination product as a whole. In order for
a combination product to be licensed for use in the United States,
clinical studies of the biologic product used with the delivery
device are necessary to support safety and effectiveness. Early
in development of an aerosol TB vaccine, it may  be helpful for
sponsors to envision the product label as they specify the goals
of the vaccine development program. Using labeling concepts
can inform the design, conduct and analysis of clinical trials to
maximize efﬁciency of the development program. This approach
can also minimize the risk of late stage development failures,
increase the probability that optimal safety and efﬁcacy data are
obtained in a timely manner, improve labeling content and possi-
bly decrease the time to overall development. For more detailed
guidance on the use of labeling concepts, sponsors may refer to
the following FDA Guidance for Industry and Review Staff: Target
Product Proﬁle: A Strategic Development Tool which can be found
at: http:/www.fda.gov/downloads/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/ucm080593.pdf. Although this
document refers specially to the drug development process, the
general approach outlined applies to biologic products as well.
Regardless of the approach used to develop a vaccine development
program, early communication with the FDA is advisable to
receive feedback on critical issues that can lead to a more efﬁcient
development and approval process.
Dr. Lakhani addressed regulatory considerations for device sys-
tems designed to deliver aerosol vaccines. Dr.  Lakhani stressed
the importance of demonstrating that a vaccine remains potent,
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afe and effective following aerosolization by any of the available
erosol delivery devices. She described three potential device types
hat can be developed for aerosol delivery of a vaccine: the metered
ose inhaler, the dry powder inhaler and the nebulizer. Dr. Lakhani
lso discussed the use of nasal sprays, which do not deliver aerosol
accine to the lungs but may  be relevant to TB vaccine development
iven the relevance to developing a mucosal immune response in
he respiratory tract. Issues to be considered for vaccine delivery via
he metered dose inhaler include the ability to deliver a single dose
nd locking of the inhaler after the delivery. Environmental con-
amination should also be addressed with vaccine delivery using
etered dose inhalation methods [6]. The dry powder inhaler can
eliver consistent doses with possibly minimal environmental con-
amination, and the formulation of dry powder can potentially have
onger stability than liquid formulations [6]. The nebulizer is asso-
iated with signiﬁcant wastage and environmental contamination
6]. Nasal sprays, used with the licensed FluMist inﬂuenza vac-
ine, share the drawbacks of the metered dose inhaler and could
ntroduce the possibility of access to the central nervous system
CNS) via the cribiform plate [7], requiring careful scrutiny for CNS-
elated adverse events during the product development process. Dr.
akhani encouraged vaccine developers to carefully consider the
arget population and the environment in which the licensed prod-
ct ultimately would be used when selecting the delivery device.
onsidering these factors in the earliest stages of product develop-
ent will enhance the probability of developing a safe and effective
roduct. Dr. Lakhani also stressed the importance of early commu-
ication with the FDA when developing an aerosol TB vaccine.
. Session 2: Pulmonary immunology: Implications for
erosol TB vaccine strategies
Theoretical Basis for Mucosal Immunity-based Protection
gainst Mycobacterium tuberculosis Infection and/or TB Disease
ased on Evolving Concepts of Early Events in Mtb Infection. Dr.
hilana Ling Lin, Department of Pediatrics, Children’s Hospital
f Pittsburgh, University of Pittsburgh Medical Center, Pitts-
urgh, PA, USA
A better understanding of the mucosal immune response to
tb  infection and its impact on progression to active disease is
 necessary component to developing effective vaccine strate-
ies to prevent TB infection and disease, and to identifying the
otential role that aerosol delivery of TB vaccine to the lungs
ay  play in these strategies. This session focused on describ-
ng the pathophysiological events occurring between initial Mtb
nfection and progression to disease. It also examined the roles of
ucosal, humoral, and cellular immune responses, as well as innate
esponses involving pulmonary macrophages, in controlling Mtb
nfection.
Dr. Philana Ling Lin described work she and others in the lab-
ratory of Dr. JoAnne Flynn have done in cynomolgus macaques
CMs) to elucidate the pathophysiology of the earliest stages of
nfection with Mtb. Low dose (25 colony-forming units (CFU))
tb, directly delivered to the lungs of CMs  via bronchoscope, has
een demonstrated to elicit the full spectrum of human mani-
estations of Mtb  infection, from latent infection to full blown
isease [8–10]. 18F-PET-CT, a powerful and precise imaging tech-
ique which uses [18F]ﬂuorodeoxyglucose as a tracer for metabolic
ctivity with positron emission tomography co-registered with
omputed tomography, was used to visualize early granuloma for-
ation in the lungs of CMs  following bronchoscopic delivery of Mtb.
his noninvasive imaging technique is capable of detecting lesions
s small as 1 mm in diameter, allowing investigators to follow the
ynamics of granuloma formation and dissemination in an individ-
al animal over time, by size and metabolic activity, and to correlate33 (2015) 3038–3046
early events in Mtb  infection with establishment of either latent
infection or progression to active TB disease [11,12].
Following low-dose Mtb  infection via bronchoscope, approx-
imately 45% of CMs  develop active disease while the remaining
animals develop asymptomatic, latent infection. Images taken at
three weeks following infection demonstrated fewer pulmonary
granulomas in animals that ultimately developed latent infection
as compared to those animals that that later developed active dis-
ease. At six weeks after infection, a time corresponding to the peak
of the adaptive immune response, 18F-PET-CT images of CMs  that
developed latent infection demonstrated the same number of gran-
ulomas than were seen at three weeks. In contrast, the animals that
later developed active disease demonstrated an increased number
of granulomas of larger size and increasing metabolic activity at
six weeks than were seen at three weeks [13]. These results sug-
gest that if control of initial infection is achieved, such control is
determined by immunological events occurring within the ﬁrst six
weeks following infection. Dr. Lin noted that early control of infec-
tion likely depends on both innate immune responses and the rapid
deployment of adaptive immune responses. Given these ﬁndings,
future TB vaccine strategies using aerosol delivery to improve air-
way immune surveillance offer the potential of tipping the balance
in favor of controlling initial infection to prevent active TB. Alter-
natively, lung mucosal vaccination may  contribute to preventing
the establishment of latent infection through more efﬁcient elim-
ination of infectious Mtb  organisms prior to, or soon after, the
development of granulomas.
Pulmonary T-Cell Populations and Responses: Implications
for Aerosol TB Vaccine Administration. Dr. Robert Seder, Chief,
Cellular Immunology Section, Vaccine Research Center, NIAID,
NIH; Bethesda, MD,  USA
Dr. Robert Seder described pulmonary cellular immune
responses in non-human primates in response to an adenovirus-
vectored TB vaccine candidate administered via aerosol. Dr. Seder
summarized results of immunogenicity studies from a study where
he primed Indian rhesus macaques (IRMs) with intradermal Bacille
Calmette-Guérin (BCG) followed by an aerosol boost with Aeras-
402, an adenovirus-35 (Ad35) vector expressing mycobacterial
antigens 85A/B (Ag85A/B) and TB10.4 [14]. Both CD4+ and CD8+ T-
cell cytokine responses to Ag85A/B stimulation of peripheral blood
mononuclear cells (PBMCs) showed a transient increase in response
at three weeks after the aerosol boost that occurred independent
of the BCG prime. This response, however, dissipated by 10 weeks
after the aerosol boost had been received. In contrast, pulmonary
CD4+ and CD8+ T-cells collected by bronchioalveolar lavage (BAL)
demonstrated a response to Ag85A/B stimulation that was  more
than 10-fold higher than that seen in PBMCs. There was  no addi-
tional increase in the response in macaques that had received a
BCG prime compared to those that only had received the aerosol
Ad35-Ag85A/B vaccine. Moreover, the response remained elevated
10 weeks after receipt of the aerosol Ad35-Ag85A/B vaccine. Addi-
tionally, a sustained level of CD4+ T-cells capable of generating
cytokine responses to PPD within the lung was  noted, both in the
macaques that received the aerosol vaccine alone [14,15] and those
that received both the BCG prime and the Ad35-vectored boost.
In contrast, this response was  not observed in IRMs that received
intradermal BCG vaccination alone. This study provided strong sug-
gestion that aerosol delivery of the adenovirus-vectored TB vaccine
candidate generated a much more robust mucosal response than
following delivery via injection.
Despite the robust and prolonged CD4+ and CD8+ T-cell
response to Mtb  antigens after either the Ad35 vectored vaccine
alone or as a boost following a BCG prime, no protection was
observed when the macaques were challenged with 275 CFU of Mtb
administered into the right lobe of the lung via bronchoscope 12
weeks after the aerosol boost. Notably, the challenge dose of Mtb
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sed in this experiment was far higher than the repeated exposure
o only a few Mtb  organisms thought to reﬂect natural exposure
eading to infection [16,17], providing one possible explanation for
he failure of protection noted despite the robust immunogenic-
ty [14]. Additionally, IRMs are very susceptible to Mtb  infection
nd sicken and die quickly, making protection by vaccination more
ifﬁcult than in less susceptible NHP strains. A subsequent aerosol
B vaccine study is now underway using Chinese rhesus macaques
hallenged with 15 CFU Mtb  after vaccination, to better assess the
rotection resulting from aerosol vaccine administration. Disease
rogression will be monitored with weekly 18F-PET-CT imaging,
hich will provide much more sensitive information on immune
rotection and granuloma formation immediately after challenge
han did the X-ray monitoring used in the earlier study. The
accines administered via aerosol in this second study will be ade-
ovirus 5-vectored constructs containing a broader array of Mtb
ntigens than those used in the Ad35 construct, and will include
ither ESAT-6/Ag85A/B or the GSK M72  fusion protein [18–20].
he general design of the study involves an intradermal BCG prime
ollowed by a viral vector boost. Importantly, the boost of either
d5-M72 or Ad5-ESAT-6/Ag85B will involve simultaneous aerosol
nd intramuscular administration. Combining mucosal vaccina-
ion with vaccines administered by injection will attempt to elicit
mmediate effector responses in the lung while also generating a
eservoir of antigen-speciﬁc T-cells in the periphery that could be
ecruited to the lung later in infection. Finally, the boost will be
dministered later than the 10 week post-prime time point selected
n the initial study to allow the peak adaptive immune response to
he BCG prime to subside.
Potential Role of Mucosal Humoral Responses in Contribut-
ng to Aerosol Vaccine-mediated Protection from Mycobac-
erium tuberculosis infection and/or TB disease. Dr. Jacqueline
chkar, Department of Medicine and Immunology, Albert Ein-
tein College of Medicine, Bronx, NY, USA
Dr. Jacqueline Achkar addressed the potential role of humoral
mmunity in contributing to protection from Mtb infection and
isease. Antibodies, especially against polysaccharide components
f the Mtb  capsule, may  help explain the apparent protection
rom the establishment of Mtb  infection observed in individuals
ho display no signs of tuberculosis infection despite chronic
xposure to Mtb  in TB-endemic environments such as healthcare
ettings, and also may  contribute to prevention against the devel-
pment of active tuberculosis in individuals latently infected with
tb. Possible mechanisms by which antibodies might contribute
o defense against tuberculosis infection include opsonization,
hich promotes phagolysosmal fusion and intracellular killing;
ynergism between humoral and cell mediated immunity; pro-
oting the clearance of immunomodulatory antigens released by
tb; and modulating inﬂammation by activating complement [21].
xperimental evidence from mouse models of TB by a number
f independent groups demonstrated that passive antibody trans-
er can reduce disease severity and prolong survival following
tb  challenge (for example, [22–24]). In addition, experimental
B vaccines containing Mtb  derived arabinomannan, a cell wall
olysaccharide, conjugated to Ag85B resulted in 90% survival in a
ouse model at 400 days following Mtb  challenge;100% of unvac-
inated mice had died at this time point [25] (Prados-Rosales,
npublished). Mutations in mice resulting in either B cell deﬁ-
iency [26,27] or IgA deﬁciency [28,29] also increase susceptibility
o mycobacterial infection.
Dr. Achkar further described studies using two types of antigen
icroarrays to screen human antibodies from a variety of individ-
als in an effort to better deﬁne the poorly understood correlates of
mmune protection against TB. The ﬁrst, a polysaccharide microar-
ay composed of 12 fragments of arabinomannan, was  probed with
era from a healthcare worker with no evidence of Mtb  infection, a33 (2015) 3038–3046 3041
smear-negative TB patient and a smear-positive TB patient. Results
of this study demonstrated that antibodies against one arabino-
mannan fragment were absent in the TB patients but present in
the uninfected healthcare worker. In the second antigen microar-
ray study, a nucleic acid programmable protein array (NAPPA) was
created in which all 4000 Mtb  genes were printed on an array
surface and used to generate proteins using a cell-free expression
system [30]. The NAPPA protein array was then probed with sera
from latently infected controls and TB patients with and without
HIV co-infection from the United States and South Africa. Although
distinctly different antibody patterns were seen in the patient
populations being studied, actual activities and clinical implica-
tions of the distinct antibodies identiﬁed – whether potentially
protective, enhancing, or neutral – remain to be assessed. Further
study will be needed to distinguish true correlates of protection
from these microarray results.
Role of Pulmonary Macrophage Function in Controlling TB
Infection: Implications for Mucosal Delivery of TB Vaccines via
Aerosol. Dr. Larry Schlesinger, Department of Microbial Infec-
tion and Immunity, Center for Microbial Interface Biology, Ohio
State University, Columbus, OH, USA
Dr. Larry Schlesinger focused on the role of innate immune
responses, particularly involving lung-based macrophages and
dendritic cells, in mediating critical early events in Mtb  pathogen-
esis, and emphasized the importance of understanding these early
immunological responses for successful development of new TB
therapeutics and vaccine strategies. The initial pulmonary immune
response to respiratory pathogens such as Mtb  is a balance between
the activity of inﬂammation-inducing scavenger cells seeking to
destroy such pathogens, and innate immunosuppressive activ-
ity seeking to minimize inﬂammatory damage to the delicate
alveoli which could compromise gas exchange and lung function
[31–34]. Pulmonary surfactant, a surface-active lipoprotein com-
plex secreted by Type II alveolar cells to reduce surface tension in
the alveoli and prevent their collapse during expiration, also may
act as an immunosuppressant. Gene expression and immunological
studies of human alveolar macrophages cultured in the presence or
absence of surfactant and exposed to Mtb  demonstrated that sur-
factant enhanced the expression of negative regulators of inﬂam-
mation from pulmonary macrophages [35,36]. This result demon-
strates that the activity of lung macrophages is shaped by their
environment. Suppression of immune activity by this microenvi-
ronment may  represent a bottleneck for optimal immune protec-
tion against TB infection. Aerosol TB vaccine design strategies will
need to take into consideration the unique immunological environ-
ment of the lung to increase the chances of their ultimate success.
In the discussion following this session, moderated by Dr.
Richard Silver, Division of Pulmonary, Critical Care, and Sleep
Medicine, Case Western Reserve University School of Medicine,
Cleveland, OH, questions arose as to the goal of targeting vac-
cines to the lung and how mucosal immunity will be measured
following vaccination. Phase 1 trials will be small enough to per-
mit  the use of BAL-based assays for this purpose and should be
incorporated: in particular, the willingness of subjects to undergo
research bronchoscopy should be considered in the recruitment
process. In larger trials, however, immune response assays will
necessarily be limited to blood. Discussants questioned whether it
would be possible to design acceptable, later-stage clinical trials of
aerosol TB vaccine candidates if aerosol vaccines did not stimulate
robust systemic immunogenicity detectable in assays of PBMCs.
Dr. Ramanathan noted that a sponsor may  be able to determine
the cost-effectiveness of pursuing development of a product based
on the results of immunogenicity analyses in early phase studies.
From a regulatory perspective, a biologics license application for an
aerosol TB vaccine will require data to demonstrate safety and to
provide substantial evidence of effectiveness.
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. Session 3: Aerosol TB vaccine delivery: Technical
onsiderations
Vaccine Delivery via Aerosol: An Overview. Dr. Anthony
ickey, Center for Aerosols and Nanomaterials Engineering,
esearch Triangle Institute (RTI) International, Research Trian-
le Park, NC, USA
In introducing his overview of vaccine delivery via aerosol, Dr.
nthony Hickey stressed that the technology for aerosol deliv-
ry of vaccines has been developed over decades of research on
erosol treatment of asthma, chronic obstructive pulmonary dis-
ase (COPD), cystic ﬁbrosis and diabetes. It is a mature technology,
eadily available for application to TB vaccines [37–39].
A major advantage of pulmonary delivery of TB vaccines is vac-
ine delivery directly to the site of infection, a readily accessible
ucosal immune site with an enormous epithelial surface (greater
han 140 meters squared) and a thin alveolar–vascular permeability
arrier [6]. Challenges to designing an aerosol TB vaccine include
ormulation, selection of the aerosolizing device, and physiologi-
al effects potentially different from injected vaccines, including
ifferent clearance mechanisms and adverse events speciﬁc to pul-
onary delivery. Conventional aerosol delivery devices include the
ressurized metered dose inhaler (pMDI) and the dry power inhaler
DPI), both of which deliver a dry powder formulation, and nebuliz-
rs such as the commonly used PARI eFlow device, which delivers
n aqueous dose as a ﬁne mist. The ideal average particle size for
overage of the entire respiratory tract is about 4 m,  with the
ajority of particles distributed over 1 to 5 m.  Particles larger
han 10 m will be deposited in the oropharyngeal region by iner-
ial impaction, sedimentation will carry particles between 1 and
 m in size into the trachea, bronchial and bronchiolar regions,
hile particles smaller than 1 m will diffuse into alveoli [40,41].
ulmonary delivery also results in gastrointestinal tract exposure
o the vaccine when it is coughed up and swallowed, and to the
lood via drainage to lymph nodes and directly through absorption
ithin the pulmonary parenchyma.
Approaches to vaccine particle manufacture include destructive
echanical methods like crushing and grinding, and constructive
ethods involving evaporation or crystallization [42]. Spray dry-
ng has become a prominent method of particle manufacture due
o the control of manufacturing conditions, stability imparted to
he product and ease of dispersion of the powder product as an
erosol [43]. Particle size and shape are both important consider-
tions when designing aerosol vaccines as is particle density, as
ower density particles that are porous or hollow disperse into the
irways more readily than do particles with a higher density.
Dr. Hickey concluded his presentation by describing studies of
erosol delivery of BCG in a guinea pig model that resulted in
igniﬁcantly better protection against a low dose aerosol Mtb chal-
enge than subcutaneous BCG vaccination [44,45]. He noted that the
evelopment of aerosol TB vaccines is supported by readily avail-
ble technology, the role the lungs play as the site of primary TB
nfection, evidence of the potential utility of aerosol TB vaccines
rom human and animal studies completed as early as the 1950s,
nd recent success with the aerosol measles vaccine, described
arlier in this meeting.
Preclinical Models of Aerosol Delivery: Opportunities and
bstacles. Dr. Chad Roy, Tulane National Primate Research
enter; Department of Microbiology and Immunology, Tulane
niversity School of Medicine, New Orleans, LA, USA
Dr. Chad Roy described three important challenges to providing
ffective delivery of biologically active aerosols to animals: (1)
osing challenges, given nonexistent animal compliance and the
ubsequent difﬁculty in both quantifying the dose and establishing
he true nature of its physical characteristics; (2) difﬁculties at
he host interface, particularly in deﬁning the differing respiratory33 (2015) 3038–3046
tract geometry of preclinical animal models and humans; and
(3) difﬁculties with the delivery device, given that most clinically
applicable devices are inappropriate for delivering aerosols to
animal models. Aerosol concentration, respiratory mechanics,
deposition fraction and exposure duration are the critical variables
in determining the actual dose of an aerosol product delivered
to the lungs. All are more difﬁcult to control when administering
aerosols to animals as compared to administration to humans.
The investigator must take into consideration the species-speciﬁc
anatomy and the age of the animals selected for experimentation,
and note that important variables such as the depth, frequency
and volume of their respiration needed to be monitored, although
they are essentially uncontrollable. Additionally, the physical
geometry of the respiratory tract of animal models varies widely
from mice to non-human primates. Accordingly, the same size
of particle will display a different deposition pattern depending
on lung geometry of the different animals. Dr. Roy stressed the
importance of optimizing controllable variables, such as the size
of the particle, given the broad range of variables that cannot be
controlled in aerosol vaccine administration to animals [46].
Dry Powder Aerosol Vaccines for Tuberculosis: Opportunities
and Manufacturing Issues. Dr. Eric Tsao, Vice President, Techni-
cal Operations, Aeras, Rockville, MD,  USA
Dry powder vaccines represent a promising formulation strat-
egy for aerosol vaccine delivery. Dr. Eric Tsao described some of
the critical issues involving the manufacture of dry powder vac-
cines, and the beneﬁts of dry powder formulation [47,48]. At Aeras,
dry powder adenovirus TB vaccines have been produced using a
spray dying process that results in free ﬂowing, non-hygroscopic
particles with a size range of 1 to 5 m [49]. This dry powder vac-
cine retains biological potency and has a long shelf life and good
thermal stability. Particle porosity and shape can be controlled by
varying manufacturing parameters. Excipients, which include sta-
bilizers, surfactants and adjuvants, must be optimized. The dry
powder adenovirus TB vaccine produced by Aeras has excellent
stability, even at 37 ◦C. Minimal loss of infectivity was observed
when the dry powder was stored for 5 weeks at 37 ◦C, 12 months at
25 ◦C, or 45 months at 4 ◦C. Four dry powder inhalers are currently
being evaluated prior to delivery device selection, with a reach-
able range of 1012 viral particles per dose. Additionally, a study of a
powdered TB vaccine containing recombinant Mtb  proteins conju-
gated to a TLR2 ligand adjuvant demonstrated enhanced pulmonary
immunogenicity and a degree of protection against Mtb  challenge
in a mouse model [50].
In the discussion following this session, the percentage of parti-
cles that reach alveoli in the deep lung was  questioned. Optimally,
ﬁfty percent to sixty percent of the vaccine dose should reach the
alveoli if the vaccine consists of proper sized particles. Dr. Henao-
Restrepo commented that, in the experience of the WHO  aerosol
measles vaccine team, delivery device selection should focus on
ease of use by the end user, as they found different devices to have
essentially equivalent performance.
4. Session 4: Development of aerosol vaccines for
tuberculosis: Current experience
Aerosol BCG Vaccine. Dr. Peter Beverley, Nufﬁeld Department
of Medicine, University of Oxford, Oxford, UK
There is general agreement that BCG, used globally to prevent
in infants the development of serious complications of Mtb infec-
tion, such as TB meningitis or miliary TB, is inadequate to prevent
TB disease or infection in adolescents or adults. Dr. Peter Bever-
ley suggested that the apparent lack of BCG efﬁcacy in these older
populations may  stem from an inappropriate administration strat-
egy, and that pulmonary BCG delivery may  be the only way to
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ctivate a population of lung resident T-cells with this vaccine.
hese cells can inhibit early growth of Mtb  and cannot be acti-
ated by parenteral vaccination. Based on murine experimental
ata, optimal delivery of BCG may  require both parenteral and
ulmonary administration of the vaccine [51–53].
Dr. Beverly described the advantages BCG offers as a TB vaccine,
dvantages accrued, in part, due to its long history of use in humans
nd animals. BCG is a safe vaccine with well-known side effects.
dditionally, aerosol BCG has been administered safely to humans
n clinical trials since at least the 1960s [54,55], and is the only
B vaccine shown to provide a degree of protection to Mtb  chal-
enge in species including mice, guinea pigs, cattle and non-human
rimates.
Dr. Beverley presented data comparing the efﬁcacy of intrader-
al  BCG delivery, endobronchial BCG delivery and simultaneous
ntradermal and endobronchial delivery in protecting NHPs from
n inhaled challenge with Mtb  (collaboration with Drs. E. Tchilian,
 Vordermeier and B. Villarreal-Ramos). Following Mtb  challenge
t 16 weeks after immunization, sacriﬁce and necropsy at 28 weeks
evealed that pulmonary pathology was reduced by about half in
he endobronchial and simultaneously intradermally-immunized
nimals. In contrast, the lung pathology of animals vaccinated with
ntradermal BCG alone was similar to that of unvaccinated animals.
Similar studies of simultaneous pulmonary and parenteral
mmunization in cattle more deﬁnitively demonstrated enhanced
rotection against Mtb-induced pulmonary pathology by simul-
aneous immunization (collaboration with Drs. E. Tchilian, M
ordermeier and B. Villarreal-Ramos). Calves were immunized
ith subcutaneous BCG, endobronchial BCG, simultaneous BCG in
oth locations, and simultaneous subcutaneous BCG and endo-
ronchial Ad5-Ag 85A vaccines. A Mycobacterium bovis challenge
t 12 weeks after immunization was followed by post-mortem
tudies at 24 weeks. Lung and lymph node pathology scores were
owest in the animals immunized simultaneously, with the low-
st number of granulomas occurring in the simultaneous BCG and
d5-Ag85A vaccinated animals. Dr. Beverley concluded by noting
hat a repeat comparison of parenteral or pulmonary or simulta-
eous immunization by BCG followed by a low dose aerosol Mtb
hallenge, and a direct comparison of simultaneous immunization
nd a prime/boost regimen, would be highly desirable, as would a
uman Phase 1 trial of pulmonary BCG.
Aerosol MVA85A. Dr. Sally Sharpe, Public Health England,
icrobiology Services, Porton Down, Salisbury, UK
Dr. Sally Sharpe presented data from Dr. Helen McShane’s group
t the University of Oxford on efﬁcacy and immunogenicity of
erosol TB vaccines in nonhuman primates and in humans, respec-
ively. Comparison of intradermal BCG alone with an intradermal
CG prime followed by an intratracheal BCG boost at Week 11 in
onhuman primates found no difference in survival or measures
f Mtb-induced pulmonary and extrapulmonary disease burden
etween these two vaccination regimens following an Mtb  chal-
enge by a dose of between approximately 800 and 1300 CFU at
eek 21 [56].
A subsequent study in NHPs used the modiﬁed vaccinia Ankara-
ectored Ag 85A (MVA85A) TB vaccine candidate as a boost
elivered either intradermally or by aerosol after an intrader-
al  BCG prime. Both systemic and pulmonary boosts induced an
mmune response in PMBCs and in lung CD4+ T-cells. The most
triking difference in immunogenicity between the two delivery
outes was the absence of detectable antibody responses against
he MVA  vector with the aerosol boost, a useful property for vaccine
esign strategies.Dr. Sharpe described the results of a phase 1 trial in humans
esigned to assess aerosol TB vaccine safety and immunogenic-
ty [57]. This trial was performed with 22 BCG-vaccinated adults
ho received 107 plaque-forming units (PFU) of MVA85A either33 (2015) 3038–3046 3043
intradermally or by aerosol. Systemic and pulmonary immune
responses were examined in blood and pulmonary T-cells, respec-
tively, the latter obtained by BAL performed 7 days after receiving
the MVA85A boost. The aerosol vaccine, delivered by nebu-
lizer, was well tolerated. IFN-gamma ELISPOT analysis of PBMCs
demonstrated strong antigen speciﬁc responses that did not dif-
fer between delivery routes. No difference in immune response
between the two  routes was  seen when whole blood CD4+ T-
cell responses following Ag85A stimulation were measured. In
contrast, pulmonary CD4+ T-cell responses speciﬁc for Ag85A
were stronger following aerosol delivery as compared to par-
enteral administration. Additionally, aerosol vaccine delivery was
found to be at least equal to, and possibly more potent than, par-
enteral vaccine administration at inducing IFN-gamma responses
in CD8+ T-cells from both BAL and whole blood. As in the NHP
study, aerosol immunization did not induce antibody to the MVA
vector.
Aerosol PPD and Ag85B.CpG. Dr. Daniel Hoft, Department of
Molecular Microbiology and Immunology, Saint Louis Univer-
sity, St. Louis, MO,  USA
Dr. Daniel Hoft explained that numerous immune cell subsets,
including phosphoantigen-responsive  T-cells, lipid-speciﬁc,
CD1a,b,c-restricted  T-cells and MR1-restricted Vh7.2/m19+
mucosa associated invariant T-cells (MAITs), may  be important in
mediating TB speciﬁc mucosal immunity [58,59]. Using a mouse
model of intranasal (IN) vaccine administration, Dr. Hoft tested a
protein antigen vaccine containing the Mtb Ag85B protein adju-
vanted with CpG, an oligonucleotide stimulator of toll-like receptor
9 (TLR9), subsequent to a BCG prime. Vaccine efﬁcacy was assessed
by protection against IN challenge with a green ﬂorescent protein
(GFP)-expressing BCG. While none of the vaccine regimens suc-
ceeded in completely preventing the establishment of infection,
the strategy providing the greatest degree of protection, as mea-
sured by plating homogenized lungs on kanamycin selective agar
to detect GFPrBCG by kanamycin-resistance and UV ﬂuorescence,
was a BCG prime followed by two intranasal Ag85A/CpG boosts
[60].
Dr. Hoft noted that oral vaccination with BCG represented the
earliest means by which BCG vaccination was administered, and
has been proven to be safe. A human, placebo controlled BCG trial
compared oral and intradermal (ID) delivery of a BCG priming vac-
cine followed in 12 months by a BCG boost. There were six groups
in the trial, each containing 10 TB- and HIV-uninfected adults. BCG
vaccines were administered in the following ways: ID prime alone,
ID prime and ID boost, oral prime alone, oral prime and oral boost.
The remaining two groups tested simultaneous ID and oral prime
alone, and simultaneous oral and ID prime and oral and ID boost.
Oral vaccination was  associated with higher levels of LAM-speciﬁc
IgA in nasal washes and with increased numbers of Mtb-speciﬁc
T-cells within BAL samples. In addition, oral BCG upregulated the
expression of the lung trafﬁcking signals CXCR3 in bronchioalve-
olar cells and 41 in peripheral blood mononuclear cells to a
greater extent than did intradermal BCG vaccination. Oral BCG vac-
cination led to up to 6-fold increase in recent lung emigrant CD4+
T-cells, as identiﬁed by their CXCR3 status; while mucosal blood T-
cells in peripheral blood, identiﬁed by increased 41 expression,
increased to a lesser extent.
Microarray studies were performed to better understand
changes in gene expression patterns associated with T-cell activa-
tion at Day 7 and T-cell memory at Day 56, as well as transcriptional
differences between oral and intradermal BCG administration at
the same time points. Five hundred and twenty unique genes expe-
rienced a greater than 1.3 fold change in expression at Day 7 when
compared to Day 0; some of these genes may  represent predictive
biomarkers for immune protection. By Day 56, 311 unique genes
displayed a 1.3 fold change in gene expression when compared to
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ay 0 which may  represent a T-cell memory signature. Systems
iology studies will be expanded with the goal of identiﬁca-
ion of genes involved in immunological protection against TB
nfection.
Aerosol Ad5/85A. Dr. Zhou Xing, Department of Pathology
nd Molecular Medicine, McMaster Immunology Research Cen-
er, McMaster University, Hamilton, Ontario, Canada
Dr. Zhou Xing described vaccination strategies to elicit enhanced
rotective immunity on the respiratory mucosal surface that will
rovide a more rapid immunological response to infection. Fol-
owing Mtb  infection of naïve mice, bacteria replicate rapidly in
he lungs during the ﬁrst 14 days of infection, and only begin to
low down when the adaptive immune response begins around 21
ays post-infection [61–63]. Even animals that have received sub-
utaneous BCG vaccination demonstrate a delayed airway CD4+
-cell response, which only begins 14 days after the Mtb  chal-
enge, too late to protect against the initial rapid bacterial build
p. This “immunological gap” between infection and the gener-
tion of an effective, adaptive immune response partially results
rom the ability of Mtb  to avoid and modulate the immune system,
ost signiﬁcantly by suppressing activation of infected alveolar
acrophages and dendritic cells. The airway luminal T-cells appear
o be elicited only by mucosal immunization, not by parenteral
mmunization [64–66]. Such T-cells may  hold the key to efﬁcient
rotection in the lung.
Dr. Xing described results from animal and human studies
f a human, replication-defective adenovirus 5 vaccine express-
ng Mtb  Ag85A (AdHu5Ag85A). This construct has been tested in
reclinical models including mouse, guinea pig, goat and cattle.
ollowing BCG priming in mice or guinea pigs, respiratory mucosal
oosting with AdHu5Ag85A induces much better T-cell responses
nd TB protection in the lung than intramuscular boosting [64].
ecent Phase 1 trials of this vaccine in humans using intramus-
ular delivery proved to be safe and immunogenic in individuals
ho previously were BCG immunized and in BCG naïve healthy
dults, although the vaccine was more immunogenic and activated
oth CD4+ and CD8+ T-cells in BCG primed individuals [67]. The
dHu5Ag85A vaccine subsequently was tested in BCG-primed Chi-
ese rhesus macaques as a boost via intramuscular, intratracheal
r aerosol delivery. The initial data analysis indicates that following
 low dose Mtb  challenge (25 CFU), the boost-vaccinated animals,
articularly those boosted via the respiratory routes, were better
rotected.
The McMaster vaccine trial team, in partnership with Aeras, is
urrently developing a Phase 1 human trial to evaluate the safety
nd immunogenicity of aerosol administration of AdHu5Ag85A in
reviously BCG vaccinated healthy volunteers in Canada. This trial
ill involve a dose escalation from 106 to 107 to 108 PFU, with
he highest dose compared following aerosol and intramuscular
eliveries.
In the discussion following this session, presenters were queried
s to the possible mechanisms by which aerosol administration of
B vaccines might contribute to control of TB disease and infection,
hen administered to an at-risk population that could be assumed
o have been primed with parenteral BCG during infancy. Panelists
ommented that aerosol boosts could serve to activate immuno-
ogical memory in and around the pulmonary mucosal surface, the
ite of both initial infection and granuloma formation. Panelists
oted that an optimal BCG-boosting approach may  include simulta-
eous administration of a vaccine via parenteral and aerosol routes.
anelists hypothesized that boosting at regular intervals may  be
eeded to maintain adequate mucosal immune protection in the
ung, in populations at high risk of TB infection, such as schoolchil-
ren in Cape Town, commuters on micro-buses in areas highly
ndemic for TB, or household contacts of persons known to have
ctive TB disease.33 (2015) 3038–3046
5. Summary panel discussion: Consensus points and paths
forward
Panel Chair: Dr. W.  Henry Boom, Tuberculosis Research
Unit, Department ofmedicine, Case Western Reserve University
School of Medicine, Cleveland, OH, USA.
Panel members
Dr. Tom Evans, CEO, Aeras, Rockville, MD  USA
Dr. Willem Hanekom, Deputy Director, Tuberculosis, Bill and
Melinda Gates Foundation, Seattle, WA,  USA
Dr. Anthony Hickey
Dr. Christine Sizemore.
The ﬁnal panel discussion considered the question of who
should receive an aerosol TB vaccine. The most effective use of such
a vaccine is to interrupt TB transmission by targeting adults and
adolescents. This age group is also better at inhaling than infants
and young children, making an aerosol vaccine delivery more con-
sistent, whether it is administered as a dry powder or in liquid
form in a nebulizer. Concerns about potential adverse events for
an aerosol vaccine were discussed. Panel members with regulatory
experience advised that human trials should begin with low doses
in low risk groups and gradually build up a safety record.
An effective TB vaccine is needed too urgently to stick to the
classical vaccine development strategy of extensive studies in ani-
mal  models before moving into human trials. A number of speakers
supported doing animal and human studies in parallel to accelerate
vaccine development. The great advantage of animal models is the
ability to perform a TB challenge.
The panel concluded by recognizing that there are no technical
or regulatory problems that need to be addressed before aerosol TB
vaccines can be moved into clinical development and contribute to
the diversity of vaccination approaches for TB. From a research per-
spective, aerosol vaccines have the potential to serve as tools and
thereby contribute to our understanding of the role of pulmonary
mucosal immunity in controlling Mtb  infection and disease. Speciﬁc
advantages over injected vaccines that aerosolized TB vaccines may
offer need to be elucidated through ongoing preclinical and clini-
cal assessment. The most promising vaccines must be selected to
move forward to larger human trials. Aerosol TB vaccines capable
of preventing sustained Mtb  infection, or contributing to the main-
tenance of latent infection would represent a huge step forward in
the control and eventual elimination of TB on a global scale.
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